Template:COVID-19 vaccine effectiveness
Vaccine | Initial effectiveness by severity of COVID-19 | Study location | Refs | |||
---|---|---|---|---|---|---|
Asymptomatic | Symptomatic | Hospitalization | Death | |||
Oxford–AstraZeneca | 70% (69–71%) | Not reported | 87% (85–88%) | 90% (88–92%) | Brazil | [1] |
Not reported | 89% (78–94%)[i] | Not reported | Not reported | England | [3] | |
Not reported | Not reported | Not reported | 89%[ii] | Argentina | [4] | |
72% (69–74%) | Not reported | Not reported | 88% (79–94%) | Hungary | [5] | |
Pfizer–BioNTech | 92% (91–92%) | 97% (97–97%) | 98% (97–98%) | 97% (96–97%) | Israel | [6] |
92% (88–95%) | 94% (87–98%) | 87% (55–100%) | 97%[ii] | Israel | [7][8] | |
83% (83–84%) | Not reported | Not reported | 91% (89–92%) | Hungary | [5] | |
Not reported | 78% (77–79%) | 98% (96–99%) | 96% (95–97%) | Uruguay | [9] | |
85% (74–96%) | Not reported | Not reported | England | [10] | ||
90% (68–97%) | Not reported | 100%[ii][iii] | United States | [11] | ||
Moderna | 89% (87–90%) | Not reported | Not reported | 94% (91–96%) | Hungary | [5] |
90% (68–97%) | Not reported | 100%[ii][iii] | United States | [11] | ||
Sinopharm BIBP | Not reported | Not reported | Not reported | 84%[ii] | Argentina | [4] |
69% (67–70%) | Not reported | Not reported | 88% (86–89%) | Hungary | [5] | |
50% (49–52%) | Not reported | Not reported | 94% (91–96%) | Peru | [12] | |
Sputnik V | Not reported | 98%[ii] | Not reported | Not reported | Russia | [13][14] |
Not reported | 98%[ii] | 100%[ii][iii] | 100%[ii][iii] | United Arab Emirates | [15] | |
Not reported | Not reported | Not reported | 93%[ii] | Argentina | [4] | |
86% (84–87%) | Not reported | Not reported | 98% (96–99%) | Hungary | [5] | |
CoronaVac | 54% (53–55%) | Not reported | 73% (72–74%) | 74% (73–75%) | Brazil | [1] |
Not reported | 66% (65–67%) | 88% (87–88%) | 86% (85–88%) | Chile | [16][17] | |
Not reported | 60% (59–61%) | 91% (89–93%) | 95% (93–96%) | Uruguay | [9] | |
Not reported | 94%[ii] | 96%[ii] | 98%[ii] | Indonesia | [18][19] | |
Not reported | 80%[ii] | 86%[ii] | 95%[ii] | Brazil | [20][21] | |
Sputnik Light | 79% (75–82%)[ii][iv] | Not reported | 88% (80–92%)[ii][iv] | 85% (75–91%)[ii][iv] | Argentina | [22] |
Initial course | Booster dose | Initial effectiveness by severity of COVID-19 | Study location | Refs | |||
---|---|---|---|---|---|---|---|
Asymptomatic | Symptomatic | Hospitalization | Death | ||||
CoronaVac | CoronaVac | Not reported | 80%[I] | 88%[I] | Not reported | Chile | [23] |
Pfizer–BioNTech | Not reported | 90%[I] | 87%[I] | Not reported | Chile | [23] | |
Oxford–AstraZeneca | Not reported | 93%[I] | 96%[I] | Not reported | Chile | [23] |
References
- ^ COVID-19 vaccine surveillance report (week 21) (PDF) (Technical report). Public Health England. 27 May 2021. GOV-8481.
- ^ COVID-19 vaccine surveillance report (week 20) (PDF) (Technical report). Public Health England. 20 May 2021. GOV-8401.
- ^ a b c "Ministros de Salud de todo el país consensuaron redoblar esfuerzos para completar los esquemas de vacunación en mayores de 40 años" [Health ministers from all over the country agreed to redouble their efforts to complete vaccination schedules in people over 40 years of age] (in Spanish). Government of Argentina. Ministry of Health (Argentina). 1 July 2021. Retrieved 12 July 2021.
- ^ ISSN 1198-743X.
- PMID 33964222.
- PMID 33626250.
- ^ "Real-World Evidence Confirms High Effectiveness of Pfizer–BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared". Pfizer. 11 March 2021. Retrieved 1 April 2021.
- ^ a b "Tercer estudio de efectividad de vacunación anti SARS-CoV-2 en Uruguay al 30 de junio de 2021" [Third study of effectiveness of vaccination against SARS-CoV-2 in Uruguay as of June 30, 2021]. Ministerio de Salud Pública (in Spanish). 3 July 2021. Retrieved 7 July 2021.
- PMID 33901423.
- ^ PMID 33793460.
- ^ Silvia-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernández-Navarro M, Moscoso-Porras M, Solari L, Mayta-Tristan P (22 July 2021). Efectividad de la vacuna BBIBP-CorV para prevenir infección y muerte en personal de salud [Effectiveness of the BBIBP-CorV vaccine to prevent infection and death in health personnel] (Technical report) (in Spanish). Ministry of Health of Peru. Tabla 4, figura 2.
- ^ "Russia's Sputnik V vaccine 97.6% effective in real-world study". Reuters. Moscow. 19 April 2021. Retrieved 21 April 2021.
- ^ "Sputnik V demonstrates 97.6% efficacy according to analysis of data from 3.8 million vaccinated persons in Russia making it the most efficient COVID-19 vaccine in the world" (Press release). Moscow: Russian Direct Investment Fund. 19 April 2021. Retrieved 21 April 2021.
- ^ "Sputnik V has demonstrated 97.8% efficacy against COVID cases and 100% efficacy against severe cases of COVID in UAE" (Press release). Moscow: Russian Direct Investment Fund. 29 June 2021. Retrieved 2 July 2021.
- S2CID 235766915.
- ^ "Reporte COVID-19: Vacuna Coronavac Tiene Un 90,3% De Efectividad Para Prevenir El Ingreso a UCI" [COVID-19 report: CoronaVac vaccine is 90.3% effective in preventing admission to the ICU]. Ministerio de Salud – Gobierno de Chile (in Spanish). 17 May 2021.
- ^ Aditya A. "China Sinovac Shot Seen Highly Effective in Real World Study". Bloomberg. Retrieved 15 May 2021.
- ^ "Kajian Cepat Kemenkes : Vaksin Sinovac Efektif Cegah Kematian" [Ministry of Health Quick Study: Sinovac Vaccine Effectively Prevents Death]. Sehat Negeriku (in Indonesian). 12 May 2021. Retrieved 15 May 2021.
- ^ "Mass vaccination creates healthy oasis in Brazilian city". Reuters. 31 May 2021. Retrieved 2 June 2021.
- ^ "Sinovac vaccine restores a Brazilian city to near normal". Associated Press. 1 June 2021. Retrieved 2 June 2021.
- PMC 8435263.